The incretin-based drugs glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin, are both used as glucose-lowering therapy for type 2 diabetes mellitus [2, 3]. Here, DPP4 is linked to diabetes mellitus.